Wedbush Reiterates Outperform Rating for Telix Pharmaceuticals (NASDAQ:TLX)

Telix Pharmaceuticals (NASDAQ:TLX)‘s stock had its “outperform” rating reaffirmed by investment analysts at Wedbush in a research report issued on Thursday,Benzinga reports. They presently have a $22.00 price target on the stock. Wedbush’s price target would suggest a potential upside of 78.86% from the company’s current price.

TLX has been the subject of several other research reports. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Telix Pharmaceuticals in a research report on Friday, July 17th. Citigroup restated a “buy” rating on shares of Telix Pharmaceuticals in a research report on Thursday. Royal Bank Of Canada downgraded shares of Telix Pharmaceuticals from an “outperform” rating to a “sector perform” rating in a report on Friday, July 17th. Finally, HC Wainwright reiterated a “buy” rating and set a $20.00 price target on shares of Telix Pharmaceuticals in a research report on Tuesday, July 7th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $20.40.

Telix Pharmaceuticals Trading Up 1.5%

NASDAQ TLX traded up $0.18 during midday trading on Thursday, hitting $12.30. The company had a trading volume of 180,019 shares, compared to its average volume of 195,443. The firm has a 50-day moving average price of $10.87 and a 200-day moving average price of $9.60. The company has a debt-to-equity ratio of 1.08, a current ratio of 1.43 and a quick ratio of 1.27. Telix Pharmaceuticals has a twelve month low of $6.28 and a twelve month high of $12.60.

Telix Pharmaceuticals (NASDAQ:TLX) last released its earnings results on Thursday, August 20th. The company reported $0.05 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.04 by $0.01. The company had revenue of $238.68 million for the quarter, compared to analyst estimates of $479.63 million. On average, analysts expect that Telix Pharmaceuticals will post 0.05 EPS for the current fiscal year.

Institutional Investors Weigh In On Telix Pharmaceuticals

A number of hedge funds have recently made changes to their positions in the stock. Lazard Asset Management LLC grew its holdings in shares of Telix Pharmaceuticals by 15.7% during the 1st quarter. Lazard Asset Management LLC now owns 289,917 shares of the company’s stock valued at $2,775,000 after purchasing an additional 39,400 shares during the last quarter. Portland Investment Counsel Inc. lifted its stake in Telix Pharmaceuticals by 108.0% in the 4th quarter. Portland Investment Counsel Inc. now owns 266,200 shares of the company’s stock valued at $2,063,000 after purchasing an additional 138,200 shares during the last quarter. Millennium Management LLC bought a new position in Telix Pharmaceuticals in the 3rd quarter valued at approximately $1,883,000. Private Advisor Group LLC boosted its position in Telix Pharmaceuticals by 276.3% in the first quarter. Private Advisor Group LLC now owns 174,415 shares of the company’s stock valued at $1,669,000 after buying an additional 128,070 shares in the last quarter. Finally, Hennion & Walsh Asset Management Inc. acquired a new stake in Telix Pharmaceuticals in the second quarter valued at approximately $1,731,000.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.